Veracyte
VCYTAlgoritmens signaler
- ›Starkt 3m-momentum (+40.7%)
- ›Starkt 12m-momentum (+90.5%)
- ›Hög volatilitet (86% årlig)
- ›+98% från 52v-botten
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsVeracyte (VCYT) Stock Sinks As Profit Strength Meets Reimbursement Doubt - simplywall.st
1 d sedanVeracyte (VCYT) Stock Sinks As Profit Strength Meets Reimbursement Doubt simplywall.st
simplywall.stA Look at Veracyte Inc (VCYT) After 22.6% Decline -- GF Value $3 - GuruFocus
2 d sedanA Look at Veracyte Inc (VCYT) After 22.6% Decline -- GF Value $3 GuruFocus
GuruFocusVeracyte, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VCYT) 2026-07-31 - Seeking Alpha
2 d sedanVeracyte, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VCYT) 2026-07-31 Seeking Alpha
Seeking AlphaIs Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance? - Yahoo Finance
2 d sedanIs Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance? Yahoo Finance
Yahoo FinanceVeracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
3 d sedanVeracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates Yahoo Finance
Yahoo FinanceEarnings Flash (VCYT) Veracyte, Inc. Posts Q2 Adjusted EPS $0.54 per Share, Vs. FactSet Est of $0.43 - Moomoo
3 d sedanEarnings Flash (VCYT) Veracyte, Inc. Posts Q2 Adjusted EPS $0.54 per Share, Vs. FactSet Est of $0.43 Moomoo
MoomooVCYT|Veracyte Inc|Price:59.870|Chg%:+4.160 - TradingKey
4 d sedanVCYT|Veracyte Inc|Price:59.870|Chg%:+4.160 TradingKey
TradingKeyVeracyte to offer live audio webcasts for two investor chats - Stock Titan
5 d sedanVeracyte to offer live audio webcasts for two investor chats Stock Titan
Stock TitanVeracyte to Participate in Upcoming Investor Conferences
2025-11-06Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Research Healthcare Conference – New York, NY Fir
VeracyteBusiness WireVeracyte Announces Third Quarter 2025 Financial Results
2025-11-04Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “We delivered another outstanding quarter of tes
VeracyteBusiness WireVeracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
2025-11-03Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research
VeracyteBusiness WireVeracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
2025-10-15Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November
VeracyteBusiness WireVeracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
2025-09-28Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molec
VeracyteBusiness WireVeracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
2025-09-24Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men wit
VeracyteBusiness WireVeracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
2025-09-09Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting, taking
VeracyteBusiness WireVeracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
2025-08-29Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50
VeracyteBusiness Wire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.